More Argenica Therapeutics Ltd news
Argenica Therapeutics LtdASX: AGN

Grant Secured to Advance Pre-Clinical Studies Of ARG-007

Jul 20, 2021 at 11:42 PM EDT · Issued by Argenica Therapeutics Ltd

Filed with ASX · Jul 20, 2021 at 11:42 PM EDT · 4 pages · English

On 6ix: 6ix.com/news/grant-secured-to-advance-pre-clinical-studies-of-arg-007

Argenica Therapeutics Ltd on 6ix

Earlier from Argenica Therapeutics

  • Study Additional InformationJul 13, 2021
  • Study Shows ARG-007 Does Not DegradeJul 12, 2021
  • Argenica Completes Pilot Pre-Clinical Pharmacokinetics StudyJul 1, 2021

Later from Argenica Therapeutics

  • Appendix 4E & Annual Report 30 June 2021Aug 26, 2021
  • Argenica Achieves Manufacturing MilestonesSep 13, 2021
  • Argenica Partners With Linear For Phase 1 Clinical TrialSep 30, 2021
  • Phase 1 Clinical Trial Overview & RoadmapOct 17, 2021
  • Positive Preclinical Data for ARG-007 Neuroprotection in HIENov 2, 2021
All Argenica Therapeutics news releases↗

Follow Argenica Therapeutics into a list and get an email when it puts out news.

Follow Argenica Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer